ERRATUM

Hearing subclassification may predict long-term auditory outcomes after radiosurgery for vestibular schwannoma patients with good hearing

TO THE READERSHIP: Errors appeared in an article by Mousavi et al. (Mousavi SH, Niranjan A, Akpınar B, et al: Hearing subclassification may predict long-term auditory outcomes after radiosurgery for vestibular schwannoma patients with good hearing. *J Neurosurg* 125:845–852, 2016).

There were two slight errors in Table 1. The correct percentage of male vestibular schwannoma patients with Gardner-Robertson Class I-B2 hearing should have been 61% (35 of 57 patients), and the correct percentage of female patients with Gardner-Robertson Class I-B2 hearing should have been 39% (22 of 57 patients). See the corrected Table 1 on the following page.

Intermittently throughout the paper, the classification of hearing was erroneously named “Gardner-Robinson” rather than “Gardner-Robertson.”

The corrected article has been posted online as of March 24, 2017.

Gillian Shasby

Director of Publications–Operations
Journal of Neurosurgery Publishing Group, Charlottesville, VA

INCLUDE WHEN CITING

Published online March 24, 2017; DOI: 10.3171/2017.3.JNS151624a.

©AANS, 2017

TABLE 1. Characteristics of the 166 vestibular schwannoma patients at the time of SRS*

Characteristic	Class I-A	Class I-B1	Class I-B2	Overall
Age in yrs				
Median	46	50	51	49
Range	20 to 71	25 to 71	28 to 68	20 to 71
Sex				
Male	19 (36%)	27 (48%)	35 (61%)	81 (49%)
Female	34 (64%)	29 (52%)	22 (39%)	85 (51%)
Presenting symptoms before SRS				
Hearing loss only	0	10	18	28
Observational management before hearing loss onset	0	21	18	39
Tinnitus	21	0	0	21
Tinnitus + hearing loss	0	28	28	56
Tinnitus + other symptoms	12	0	0	12
Hearing loss + other symptoms	0	18	11	29
Vertigo	4	0	0	4
Imbalance	1	0	0	1
Trigeminal neuropathy	0	0	0	0
Facial neuropathy	1	0	0	1
Headache	3	0	0	3
Incidental	11	0	0	11
PTA (dB)				
Tumor-affected ear				
Median	10	17	25	17
Range	0 to 30	5 to 28	12 to 30	0 to 30
Non-tumor-affected ear				
Median	7	10	9	9.5
Range	0 to 23	0 to 25	0 to 18	0 to 25
Difference in PTA, tumor side vs normal side (dB)				
Median	2	5	15	7
Range	-8 to 23	-5 to 15	11 to 23	-8 to 23
SDS (%)				
Tumor-affected ear				
Median	100	96	92	96
Range	82 to 100	70 to 100	76 to 100	70 to 100
Non-tumor-affected ear				
Median	100	100	100	100
Range	92 to 100	90 to 100	80 to 100	80 to 100
Tumor vol (cm ³)				
Median	0.74	0.69	1.0	0.80
Range	0.12 to 12.8	0.10 to 9.8	0.12 to 7.7	0.10 to 12.8
Details of SRS, Gy				
Tumor marginal dose				
Median	12.5	12.5	12.5	12.5
Range	12 to 13	12 to 13	12 to 13	12 to 13
Maximum dose				
Median	25	25	25	25
Range	17.8 to 26	18.6 to 26	20.8 to 26)	17.8 to 26

* Values represent number of patients unless indicated otherwise.